Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations.

ABSTRACT:

Background

Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk of developing adverse reactions and treatment failure in COVID-19 patients. Aim of our study was to identify pharmacogenes and pharmacogenomics markers associated with drugs recommended for COVID-19 treatment, chloroquine/hydroxychloroquine, azithromycin, lopinavir and ritonavir, in population of Serbia and other world populations.

Methods

Genotype information of 143 individuals of Serbian origin was extracted from database previously obtained using TruSight One Gene Panel (Illumina). Genotype data of individuals from different

SUBMITTER: Stankovic B 

PROVIDER: S-EPMC7710379 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature